Position in ANNX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$1,108,000
New position
Shares Held
200,000
first reported quarter
Ownership
0.100%
of shares outstanding
% of Portfolio
0.45%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rosalind Advisors, Inc. holds $166,757,300 across 22 Biotechnology names. ANNX ranks #21 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FENC |
Fennec Pharmaceuticals Inc.
|
2,908,201 | $17,885,436 | |
| 2 | SVRA |
Savara Inc
|
3,203,721 | $17,492,316 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
290,000 | $16,851,900 | |
| 4 | EYPT |
EyePoint, Inc.
|
1,036,737 | $13,363,539 | |
| 5 | XFOR |
X4 Pharmaceuticals, Inc
|
3,214,766 | $13,276,983 | |
| 6 | VOR |
Vor Biopharma Inc.
|
700,000 | $12,488,000 | |
| 7 | MDWD |
MediWound Ltd.
|
749,054 | $12,067,259 | |
| 8 | VSTM |
Verastem, Inc.
|
2,138,475 | $11,333,917 |
All Filings in ANNX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,108,000 | 200,000 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||